PERTH, Australia – Adelaide-based Bionomics Inc. is reviving lead compound BNC-210 after a deeper analysis of phase II data showed a positive effect in post-traumatic stress disorder (PTSD). Read More
HONG KONG – Shenyang, China-based 3Sbio Inc. has signed a partnership agreement with Verseau Therapeutics Inc., of Lexington, Mass., to develop and commercialize monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. The collaboration will be based on Verseau's drug discovery platform, which generates first-in-class macrophage checkpoint modulators (MCMs) to treat patients with cancer, immune and inflammatory diseases. Read More
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640. Read More
HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. has out-licensed its core asset FP-001 (leuprorelin depot) for treating prostate cancer to U.K.-based Accord Healthcare in an $86 million deal. Read More
PERTH, Australia – Although industry stakeholders were generally supportive of New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) proposed changes to the reclassification system for drugs in New Zealand, most vehemently opposed the idea of posting completed applications on the Medsafe website, citing competitive intellectual property concerns. Read More
Wuxi Biologics Inc., of Shanghai, and Amicus Therapeutics Inc., of Cranbury, N.J., inked an exclusive commercial manufacturing partnership covering ATB-200, the alpha-glucosidase stimulator that Amicus is advancing in Pompe disease. Wuxi will enable and support Amicus with global sourcing and will manufacture both the drug substance and product at two sites across its commercial supply network. Read More
